Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KARS1 | Q15046 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL267558 | 1.00 | KARS1 (0.38) | KARS1MEN1TP53CYP3A4MAPT | |
| SCHEMBL12522482 | 0.92 | KARS1 (0.41) | KARS1MEN1TP53CYP3A4MAPT | |
| SCHEMBL14112200 | 0.92 | KARS1 (0.41) | KARS1MEN1TP53CYP3A4MAPT | |
| SCHEMBL14260996 | 0.92 | KARS1 (0.41) | KARS1MEN1TP53CYP3A4MAPT | |
| SCHEMBL12522483 | 0.92 | KARS1 (0.41) | KARS1MEN1TP53CYP3A4MAPT | |
| SCHEMBL10219385 | 0.92 | KARS1 (0.41) | KARS1MEN1TP53CYP3A4MAPT | |
| SCHEMBL10219384 | 0.92 | KARS1 (0.41) | KARS1MEN1TP53CYP3A4MAPT | |
| SCHEMBL12887769 | 0.92 | KARS1 (0.41) | KARS1MEN1TP53CYP3A4MAPT | |
| SCHEMBL14286834 | 0.92 | KARS1 (0.41) | KARS1MEN1TP53CYP3A4MAPT | |
| SCHEMBL280434 | 0.85 | CYP19A1 (0.39) | NR1H3PTPN1PTGS1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238634-A1 | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS | NEREUS PHARMACEUTICALS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| EP-1912932-B1 | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-A MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS | NEREUS PHARMACEUTICALS INC (US) | 2012-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238634-A1 | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS | IL1A, IL1B, TNF | KARS1 3304/4885MEN1 54/4885TP53 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.